Clarivate
OCTOBER 25, 2023
The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.
Pharmaceutical Technology
SEPTEMBER 2, 2022
Since the frontline treatment setting is dominated by these regimens, pharma companies have focused on the development of new drugs in the relapsed/refractory (R/R) setting. However, the lack of mature overall survival data for either agent means physicians will have to select therapy based on attributes other than long-term efficacy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PM360
APRIL 7, 2023
No one has ever described the pharma market access landscape as simple or easy to understand, and the passage of the Inflation Reduction Act (IRA) is not likely to change that. Pharma manufacturers of brands that are selected for negotiation will absolutely want to ‘pull through’ their coveted, newfound formulary position with HCPs.
Clarivate
APRIL 18, 2024
But, even without Amedisys, the insurer still has home healthcare company LHC Group, acquired in early 2023, and will leverage a long-term partnership with Walmart plus the nation’s largest network of employed and affiliated physicians through Optum to manage patient health and drive down costs for vulnerable patients.
pharmaphorum
OCTOBER 10, 2022
As part of efforts to increase uptake of screening programmes, purpose-driven partnerships between the NHS and the pharma industry have emerged as an innovative solution to raise patient awareness. The goal set out by the NHSE Long Term Plan is ambitions: to have three quarters of cancers diagnosed at an early stage by 2028.
Medico Reach
JUNE 16, 2022
trillion by 2028. The healthcare industry is currently undergoing a paradigm shift, and with a technology-enabled healthcare model in place, the role of general physicians will change forever. billion Pharma: $169.9 The industry was worth around 19.7% of the US GDP in 2020. The US national healthcare expenditure for 2020 was $4.1
World of DTC Marketing
DECEMBER 15, 2021
Together with the growth in wearables—projected to be worth nearly $120 billion by 2028—we are seeing growing democratization of knowledge of one’s own body, with tech enabling consumers to take a more active and regular role in their healthcare. Physicians have not bought into the hype around apps. The Economist.
Expert insights. Personalized for you.
52 
Let's personalize your content